Of the 480 respondent cancer patient groups, 45% represent patient interests to drug regulators. They most commonly participate in HTA and reimbursement reviews (26%) and advocate for equitable access to healthcare (17%).
45% of respondents from Cancer ‘Regularly’ or ‘Sometimes’ represent patient interests to drug regulators
Patient groups representing each Cancer sub-type
480 patient groups across 30 sub-types
interactions
Our organisation is a member of the Advisory Board of INCA [Instituto Nacional de Câncer – National Cancer Institute] (CONSINCA [Conselho Consultivo do INCA – Advisory Board of INCA]), CONITEC [Comissão Nacional de Incorporação de Tecnologias no SUS – National Committee for Health Technology Incorporation], and COSAÚDE [Comissão de Atualização do Rol – ANS covered-procedures committee].
Nossa organização é membro do Conselho Consultivo do INCA (CONSINCA), Conitec e COSAÚDE.
National cancer patient group, Brazil
interactions
HTAs [Health Technology Assessments] by NICE [National Institute for Health and Care Excellence], SMC [Scottish Medicines Consortium], and NCPE [National Centre for Pharmacoeconomics] for MPN [Myeloproliferative Neoplasm] drugs.
HTAs by NICE, SMC, and NCPE for MPN drugs.
National cancer patient group, UK
actions & advocacy
... In 2025, successful advocacy in collaboration with another organization before the National Health Insurance Fund [of Bulgaria] to stop a change regarding the prescription of hormonal injection therapy, which will be to the detriment of patients.
National cancer patient group, Bulgaria
actions & advocacy
... Since 2025, the government [in Taiwan] has also begun implementing its Cancer New Drug Fund policy, and our organisation is recognised as one of 13 patient advocacy groups whose efforts contributed to that successful outcome.
對於病友權利維護及新藥可近性的倡議，我們會與利害關係人、政府單位、相關專家進行溝通，表達病友的臨床需求及治療的迫切性。自2025年政府也開始執行癌症新藥基金的政策，惟本會為13個病友團體倡議之成功案例之一。
National cancer patient group, Taiwan
The percentages below highlight how the 211 patient groups interact with regulators and advocate for patient interests. As respondents may be represented in more than one area, percentages may not total 100%.
interactions
119 mentions
55 mentions
27 mentions
17 mentions
14 mentions
3 mentions
3 mentions
32 mentions
20 mentions
12 mentions
24 mentions
23 mentions
1 mention
22 mentions
12 mentions
7 mentions
2 mentions
1 mention
7 mentions
7 mentions
1 mention
1 mention
actions & advocacy
51 mentions
20 mentions
19 mentions
5 mentions
2 mentions
2 mentions
2 mentions
1 mention
44 mentions
36 mentions
6 mentions
1 mention
1 mention
27 mentions
18 mentions
5 mentions
4 mentions
7 mentions
4 mentions
2 mentions
1 mention
6 mentions
6 mentions
4 mentions
3 mentions
1 mention
GET THE REPORT
Our research covers 2,262 patient groups representing 100 countries and 45 therapy areas. The sample report shows you the depth of analysis for a single country or therapy area. To access any other reports, please get in touch.
Visit patient-view.com to gather more information or email: Alex Wyke, alexwyke@patient-view.com
